OncoHost
Binyamina, Israel· Est.
AI‑driven plasma proteomics platform that predicts immunotherapy response for oncology patients.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven plasma proteomics platform that predicts immunotherapy response for oncology patients.
OncologyImmunotherapy
Technology Platform
Plasma‑based proteomic pattern recognition combined with AI to generate a predictive PROphet score for immunotherapy benefit.
Opportunities
Expansion of the PROphet assay to additional cancer types and integration into pharma clinical trial stratification present licensing opportunities.
Risk Factors
Dependence on proteomics assay scalability, reimbursement uncertainty, and competition from genomic and transcriptomic biomarker platforms.
Competitive Landscape
Competes with DNA‑based companion diagnostics and ctDNA assays; differentiates through host‑response proteomic profiling and AI‑driven predictive scoring.